Biocon Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Biocon wird ein jährliches Gewinn- und Umsatzwachstum von 47.6% bzw. 13.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.7% betragen.
Wichtige Informationen
47.6%
Wachstumsrate der Gewinne
44.49%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 35.4% |
| Wachstumsrate der Einnahmen | 13.1% |
| Zukünftige Eigenkapitalrendite | 5.68% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 21 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Analyseartikel • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Recent updates
Analyseartikel • 19h
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Narrativ-Update • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Narrativ-Update • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Narrativ-Update • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Narrativ-Update • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Narrativ-Update • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Narrativ-Update • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Narrativ-Update • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Narrativ-Update • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Narrativ-Update • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Narrativ-Update • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Analyseartikel • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Narrativ-Update • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Analyseartikel • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Narrativ-Update • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Analyseartikel • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Narrativ-Update • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Narrativ-Update • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Analyseartikel • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Analyseartikel • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Analyseartikel • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...Analyseartikel • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Analyseartikel • Jun 18
Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50
The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
Neues Narrativ • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2029 | 249,133 | 21,939 | 24,827 | 47,141 | 6 |
| 3/31/2028 | 228,628 | 19,945 | 27,427 | 41,522 | 18 |
| 3/31/2027 | 200,534 | 13,692 | 22,775 | 38,096 | 18 |
| 3/31/2026 | 169,270 | 3,856 | 823 | 19,940 | N/A |
| 12/31/2025 | 168,274 | 6,042 | N/A | N/A | N/A |
| 9/30/2025 | 164,758 | 4,855 | 17,973 | 41,592 | N/A |
| 6/30/2025 | 157,707 | 3,850 | N/A | N/A | N/A |
| 3/31/2025 | 152,617 | 10,133 | 17,179 | 40,612 | N/A |
| 12/31/2024 | 147,618 | 8,043 | N/A | N/A | N/A |
| 9/30/2024 | 148,941 | 14,392 | 21,045 | 40,368 | N/A |
| 6/30/2024 | 147,660 | 15,808 | N/A | N/A | N/A |
| 3/31/2024 | 147,557 | 10,225 | 10,223 | 29,539 | N/A |
| 12/31/2023 | 146,125 | 12,002 | N/A | N/A | N/A |
| 9/30/2023 | 135,999 | 4,984 | -6,241 | 11,717 | N/A |
| 6/30/2023 | 124,573 | 4,197 | N/A | N/A | N/A |
| 3/31/2023 | 111,742 | 4,627 | 1,262 | 18,525 | N/A |
| 12/31/2022 | 98,091 | 3,881 | N/A | N/A | N/A |
| 9/30/2022 | 90,422 | 6,170 | -6,836 | 11,543 | N/A |
| 6/30/2022 | 85,629 | 7,084 | N/A | N/A | N/A |
| 3/31/2022 | 81,840 | 6,484 | -7,482 | 11,766 | N/A |
| 12/31/2021 | 75,800 | 6,727 | N/A | N/A | N/A |
| 9/30/2021 | 72,632 | 6,542 | -6,366 | 12,763 | N/A |
| 6/30/2021 | 71,726 | 6,852 | N/A | N/A | N/A |
| 3/31/2021 | 71,431 | 7,405 | -5,866 | 11,597 | N/A |
| 12/31/2020 | 68,913 | 5,996 | N/A | N/A | N/A |
| 9/30/2020 | 67,571 | 6,362 | -6,576 | 10,484 | N/A |
| 6/30/2020 | 65,796 | 6,870 | N/A | N/A | N/A |
| 3/31/2020 | 63,005 | 7,771 | -5,534 | 12,831 | N/A |
| 12/31/2019 | 63,150 | 8,385 | N/A | N/A | N/A |
| 9/30/2019 | 61,077 | 8,529 | N/A | 14,573 | N/A |
| 6/30/2019 | 58,565 | 9,919 | N/A | N/A | N/A |
| 3/31/2019 | 55,144 | 9,053 | N/A | 11,546 | N/A |
| 12/31/2018 | 51,551 | 8,220 | N/A | N/A | N/A |
| 9/30/2018 | 46,722 | 6,967 | N/A | N/A | N/A |
| 6/30/2018 | 43,198 | 4,108 | N/A | N/A | N/A |
| 3/31/2018 | 41,234 | 3,724 | N/A | 6,621 | N/A |
| 12/31/2017 | 38,792 | 3,695 | N/A | N/A | N/A |
| 9/30/2017 | 38,589 | 4,489 | N/A | N/A | N/A |
| 6/30/2017 | 38,361 | 5,268 | N/A | N/A | N/A |
| 3/31/2017 | 38,911 | 6,121 | N/A | 6,400 | N/A |
| 12/31/2016 | 40,487 | 11,633 | N/A | N/A | N/A |
| 9/30/2016 | 38,110 | 10,961 | N/A | N/A | N/A |
| 6/30/2016 | 36,539 | 9,388 | N/A | N/A | N/A |
| 3/31/2016 | 33,474 | 5,504 | N/A | 3,706 | N/A |
| 12/31/2015 | 32,997 | 7,367 | N/A | N/A | N/A |
| 9/30/2015 | 32,325 | 7,247 | N/A | N/A | N/A |
| 6/30/2015 | 31,528 | 5,207 | N/A | N/A | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BIOCONDas prognostizierte Gewinnwachstum (47.6% pro Jahr) liegt über der Sparquote (6.9%).
Ertrag vs. Markt: BIOCONDie Erträge des Unternehmens (47.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16.4% pro Jahr).
Hohe Wachstumserträge: BIOCONEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: BIOCONDie Einnahmen des Unternehmens (13.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.8% pro Jahr).
Hohe Wachstumseinnahmen: BIOCONDie Einnahmen des Unternehmens (13.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BIOCONDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.7%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 18:48 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Biocon Limited wird von 39 Analysten beobachtet. 18 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |